Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Fineline Cube Apr 20, 2026
Company Drug

Henan Zhongshuai’s Dexmethylphenidate Hydrochloride Capsules Target Priority Review for Pediatric ADHD

Fineline Cube Sep 7, 2023

Henan Zhongshuai Pharmaceutical Co., Ltd., a China-based pharmaceutical company, is poised to secure priority review...

Company Drug

Amneal Pharmaceuticals Receives China Approval for Sevelamer Carbonate

Fineline Cube Sep 7, 2023

US-based Amneal Pharmaceuticals Inc. (NYSE: AMRX) has announced that it has received approval from the...

Company Drug

CSPC Pharmaceutical’s Narlumosbart Approved by NMPA for Bone Giant Cell Tumors

Fineline Cube Sep 7, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, Shanghai JMT Biotechnology Co.,...

Company Drug

Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for CDE’s BTD Status

Fineline Cube Sep 7, 2023

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its HER2 targeted antibody-drug...

Policy / Regulatory

NMPA Drafts Guidelines for Supervising Online Drug Exchange Platforms

Fineline Cube Sep 7, 2023

The National Medical Products Administration (NMPA) has released draft “Online Third-party Drug Exchange Platforms Inspection...

Company Drug

Genentech Files for FDA Approval of Crovalimab for PNH, Challenging Soliris

Fineline Cube Sep 7, 2023

Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has submitted its anti-C5 investigational drug, crovalimab,...

Company Deals

uBriGene and YolTech Therapeutics Join Forces to Advance mRNA Therapy and Gene Therapy

Fineline Cube Sep 7, 2023

China-based uBriGene Biosciences Inc., a prominent contract development and manufacturing organization (CDMO) specializing in cell...

Policy / Regulatory

CDE’s 2022 Drug Review Report: A Year of Pandemic Response and Regulatory Milestones

Fineline Cube Sep 7, 2023

The Center for Drug Evaluation (CDE) has released its comprehensive 2022 annual drug review report,...

Company Drug

Hainan Haiyao Concludes Phase I Clinical Study for PaiEnJiaBin, a Novel KCNQ Agonist

Fineline Cube Sep 7, 2023

China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced the conclusion of Phase I clinical...

Company Deals

Sino Medical Sciences Technology to Acquire Majority Stake in US Endovascular Device Firm eLum

Fineline Cube Sep 7, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced plans to acquire a 72.73%...

Company Medical Device

Acotec Scientific Holdings Receives Marketing Approvals for Vericor-14 Microcatheter in Japan and Thailand

Fineline Cube Sep 7, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approvals...

Company Drug

Brii Biosciences Announces Positive Interim Data for BRII-179 Vaccine in Chronic Hepatitis B

Fineline Cube Sep 7, 2023

China-based Brii Biosciences Ltd (HKG: 2137) has announced topline cohort-level unblinded Week 36 data from...

Company Drug

MSD’s Gardasil 9 HPV Vaccine Demonstrates 10-Year Efficacy in Adolescents

Fineline Cube Sep 6, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has released long-term effectiveness data for its recombinant...

Company Deals

Sinovac Biotech Directors Reject Alternative Liquidity’s Lowball Tender Offer

Fineline Cube Sep 6, 2023

China-based Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its Board of Directors has unanimously determined...

Company Deals

Abbott to Acquire Insulin Management Firm Bigfoot Biomedical

Fineline Cube Sep 6, 2023

Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company...

Policy / Regulatory

Taizhou Port Designated as Drug Import Port by NMPA and General Administration of Customs

Fineline Cube Sep 6, 2023

The National Medical Products Administration (NMPA) and the General Administration of Customs have released a...

Company

Sandoz Reports H1 2023 Financials with 8% YOY Growth, Separation from Novartis Looms

Fineline Cube Sep 6, 2023

Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the first half of 2023,...

Policy / Regulatory

Li Li Appointed as New Director of NMPA

Fineline Cube Sep 6, 2023

The State Council has released an announcement regarding appointments and dismissals within the government. Among...

Policy / Regulatory

NHSA Mandates National Standards for Medical Consumables in Basic Medical Insurance

Fineline Cube Sep 6, 2023

The National Healthcare Security Administration (NHSA) has released a notification with a focus on enhancing...

Company Deals

Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases

Fineline Cube Sep 6, 2023

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation...

Posts pagination

1 … 465 466 467 … 654

Recent updates

  • LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment
  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
  • Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors
  • Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.